SK282607B6 - Farmaceutický prostriedok obsahujúci uhličitan lantanitý, spôsob prípravy tejto zlúčeniny a jej použitie - Google Patents

Farmaceutický prostriedok obsahujúci uhličitan lantanitý, spôsob prípravy tejto zlúčeniny a jej použitie Download PDF

Info

Publication number
SK282607B6
SK282607B6 SK1288-97A SK128897A SK282607B6 SK 282607 B6 SK282607 B6 SK 282607B6 SK 128897 A SK128897 A SK 128897A SK 282607 B6 SK282607 B6 SK 282607B6
Authority
SK
Slovakia
Prior art keywords
lanthanum
lanthanum carbonate
carbonate
formula
treatment
Prior art date
Application number
SK1288-97A
Other languages
English (en)
Slovak (sk)
Other versions
SK128897A3 (en
Inventor
Barry Anthony Murrer
Nigel Anthony Powell
Original Assignee
Anormed Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10771896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK282607(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anormed Inc. filed Critical Anormed Inc.
Publication of SK128897A3 publication Critical patent/SK128897A3/sk
Publication of SK282607B6 publication Critical patent/SK282607B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
    • C01F17/00—Compounds of rare earth metals
    • C01F17/20—Compounds containing only rare earth metals as the metal element
    • C01F17/247—Carbonates
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
    • C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Geology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SK1288-97A 1995-03-25 1996-03-19 Farmaceutický prostriedok obsahujúci uhličitan lantanitý, spôsob prípravy tejto zlúčeniny a jej použitie SK282607B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9506126.3A GB9506126D0 (en) 1995-03-25 1995-03-25 Pharmaceutical composition and method
PCT/GB1996/000575 WO1996030029A1 (en) 1995-03-25 1996-03-19 Pharmaceutical composition containing selected lanthanum carbonate hydrates

Publications (2)

Publication Number Publication Date
SK128897A3 SK128897A3 (en) 1998-10-07
SK282607B6 true SK282607B6 (sk) 2002-10-08

Family

ID=10771896

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1288-97A SK282607B6 (sk) 1995-03-25 1996-03-19 Farmaceutický prostriedok obsahujúci uhličitan lantanitý, spôsob prípravy tejto zlúčeniny a jej použitie

Country Status (28)

Country Link
US (1) US5968976A (ja)
EP (1) EP0817639B1 (ja)
JP (1) JP3224544B2 (ja)
KR (1) KR100329340B1 (ja)
CN (1) CN1102393C (ja)
AT (1) ATE209923T1 (ja)
AU (1) AU702073B2 (ja)
BR (1) BR9607926A (ja)
CA (1) CA2216437C (ja)
CZ (1) CZ293494B6 (ja)
DE (4) DE69617659T4 (ja)
DK (1) DK0817639T3 (ja)
EA (1) EA000270B1 (ja)
EE (1) EE04096B1 (ja)
ES (1) ES2170223T3 (ja)
GB (1) GB9506126D0 (ja)
HK (1) HK1008182A1 (ja)
HU (1) HU224198B1 (ja)
MX (1) MX9707334A (ja)
NO (1) NO313488B1 (ja)
NZ (1) NZ303260A (ja)
PL (1) PL184315B1 (ja)
PT (1) PT817639E (ja)
SK (1) SK282607B6 (ja)
TR (1) TR199701030T1 (ja)
TW (1) TW436288B (ja)
WO (1) WO1996030029A1 (ja)
ZA (1) ZA962369B (ja)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
BR0209072A (pt) * 2001-04-23 2006-02-07 Anormed Inc Aplicação de compostos de terra-rara para a prevenção de cálculo renal
WO2003094933A2 (en) * 2002-05-08 2003-11-20 Shire Holding Ag Use of lanthanum for the treatment of hypercalcemia and bone metastasis
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20060083791A1 (en) * 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
CN100526219C (zh) * 2002-08-14 2009-08-12 爱尔达纳米公司 稀土金属化合物、其制造方法及其使用方法
EP2194028B1 (en) * 2002-08-14 2022-01-26 Unicycive Therapeutics, Inc. Rare earth metal compounds, methods of making, and methods of using the same
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
CZ17621U1 (cs) * 2003-08-26 2007-06-25 Shire Holdings Ag Farmaceutický prostredek zahrnující slouceniny lanthanu
EA010980B1 (ru) * 2004-07-27 2008-12-30 Шир Фармасьютикалс, Инк. Способ лечения гиперфосфатемии с использованием гидроксикарбоната лантана
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
US20060134225A1 (en) * 2004-10-15 2006-06-22 Moerck Rudi E Phosphate binder with reduced pill burden
ITME20040015A1 (it) * 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
GB0502787D0 (en) * 2005-02-10 2005-03-16 Ineos Silicas Ltd Pharmaceuticlly active compounds, their manufacture, compositions containing them and their use
EP1698233A1 (en) * 2005-03-01 2006-09-06 Bayer HealthCare AG Reduction of digestibility of phosphorus in animal nutrition
US20080069860A1 (en) * 2005-08-17 2008-03-20 Allison Wren Hyperphosphatemia in domestic animals: compositions and methods of treatment
AU2006279343A1 (en) * 2005-08-17 2007-02-22 Altairnano, Inc. Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
MY157620A (en) * 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
CN100398112C (zh) * 2006-03-24 2008-07-02 辽宁诺康生物制药有限责任公司 一种治疗血磷酸盐过多症的药物及其制备方法
US20070259052A1 (en) * 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
DE202006016697U1 (de) * 2006-05-05 2007-03-08 Shire International Licensing B.V. Assay für Lanthanhydroxycarbonat
CN101077338B (zh) * 2006-05-24 2012-06-20 天津大学 纳米碳酸镧口腔崩解片及制备方法
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
US8974824B2 (en) * 2008-03-26 2015-03-10 Mylan Laboratories Ltd. Lanthanum composition
PT2389070E (pt) * 2009-01-21 2013-10-21 Mylan Inc Formulações desintegráveis de carbonato de lantânio
WO2010106557A2 (en) * 2009-03-20 2010-09-23 Panacea Biotec Limited Stable pharmaceutical formulations comprising anhydrous lanthanum carbonate and process for preparation thereof
EP2429950B1 (en) * 2009-05-15 2013-04-17 Natco Pharma Limited Process for the preparation of lanthanum carbonate dihydrate
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
JP5993368B2 (ja) 2010-05-12 2016-09-14 スペクトラム ファーマシューティカルズ インコーポレイテッド 炭酸ランタン水酸化物、ランタンオキシカルボネートならびにその製造および使用方法
EP2441436A1 (de) * 2010-10-13 2012-04-18 Fresenius Medical Care Deutschland GmbH Phosphatbinderformulierung zur einfachen Einnahme
US8263119B2 (en) 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
WO2012098562A2 (en) 2011-01-19 2012-07-26 Panacea Biotec Limited Liquid oral compositions of lanthanum salts
CN102432055B (zh) * 2011-09-23 2013-10-16 北京大学 用于治疗高磷血症的碳酸镧纳米颗粒、其制备方法及用途
CN102442692B (zh) * 2011-09-23 2014-08-27 北京大学 碳酸镧水合物的制备方法
EA021712B1 (ru) * 2012-06-12 2015-08-31 Общество С Ограниченной Ответственностью "Рубикон" Противовоспалительное средство для лечения контактного дерматита
CN103251648B (zh) 2013-05-15 2015-08-05 乔敏 治疗血磷酸盐过多症及缺铁性贫血症的铁基蒙脱石药物及其制备方法
WO2016051609A1 (ja) * 2014-10-02 2016-04-07 東和薬品株式会社 粒度調整された炭酸ランタン水和物からなる医薬
CN104473963B (zh) * 2014-12-24 2017-10-10 厦门科明达科技有限公司 稀土化学药碳酸镧咀嚼片的制备方法
US10058569B2 (en) * 2015-06-24 2018-08-28 Lupin Limited Lanthanum carbonate compositions
CN105125575B (zh) * 2015-08-07 2018-06-08 康臣药业(内蒙古)有限责任公司 一种治疗高磷酸盐血症药物的制备方法
EP3384941B1 (en) 2015-11-30 2020-12-23 Toray Industries, Inc. Porous fiber and phosphorus adsorption column
CN107876000A (zh) * 2017-10-30 2018-04-06 浙江大学 一种纳米除磷剂、制备方法及应用
CN110579499A (zh) * 2018-06-08 2019-12-17 北京华睿鼎信科技有限公司 一种碳酸镧或其制剂中碱式碳酸镧杂质的检定方法
JP7300461B2 (ja) * 2018-10-26 2023-06-29 住友化学株式会社 炭酸ランタン水和物の製造方法
CN111620363A (zh) 2020-06-13 2020-09-04 南京卡文迪许生物工程技术有限公司 一种四水合碳酸镧的制备方法及其产品
TW202202154A (zh) 2020-07-13 2022-01-16 川口恒隆 含有鈰化合物作為有效成分之醫藥組成物以及氧化鈰微粒子之製造方法
CN114477265B (zh) * 2020-11-13 2023-11-03 南京正济医药研究有限公司 一种四水碳酸镧的制备方法
CN115849429B (zh) * 2023-01-06 2024-01-23 湖南明瑞制药股份有限公司 一种小粒径四水碳酸镧的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06705B2 (ja) * 1985-12-19 1994-01-05 旭化成工業株式会社 リン酸イオンの固定化剤

Also Published As

Publication number Publication date
EP0817639B1 (en) 2001-12-05
NZ303260A (en) 2000-01-28
EA199700266A1 (ru) 1998-02-26
TR199701030T1 (xx) 1998-06-22
ZA962369B (en) 1996-11-18
PL184315B1 (pl) 2002-10-31
KR100329340B1 (ko) 2002-06-20
SK128897A3 (en) 1998-10-07
EE9700325A (et) 1998-06-15
MX9707334A (es) 1998-07-31
AU702073B2 (en) 1999-02-11
HUP9900799A3 (en) 2000-10-30
JP3224544B2 (ja) 2001-10-29
JPH11503119A (ja) 1999-03-23
WO1996030029A1 (en) 1996-10-03
KR19980703280A (ko) 1998-10-15
DE69617659T4 (de) 2007-09-27
DE69617659D1 (de) 2002-01-17
TW436288B (en) 2001-05-28
ES2170223T3 (es) 2002-08-01
CA2216437C (en) 2002-10-22
DE122007000022I1 (de) 2007-07-12
ATE209923T1 (de) 2001-12-15
AU4951496A (en) 1996-10-16
EA000270B1 (ru) 1999-02-25
DK0817639T3 (da) 2002-04-02
US5968976A (en) 1999-10-19
CN1102393C (zh) 2003-03-05
NO974425L (no) 1997-11-24
PT817639E (pt) 2002-05-31
EP0817639A1 (en) 1998-01-14
CA2216437A1 (en) 1996-10-03
GB9506126D0 (en) 1995-05-10
DE122007000022I2 (de) 2009-09-17
BR9607926A (pt) 1998-06-09
CZ293494B6 (cs) 2004-05-12
DE69617659T2 (de) 2002-10-02
HK1008182A1 (en) 1999-05-07
EE04096B1 (et) 2003-08-15
NO974425D0 (no) 1997-09-24
PL322450A1 (en) 1998-02-02
CN1184428A (zh) 1998-06-10
CZ301797A3 (cs) 1998-07-15
HU224198B1 (hu) 2005-06-28
NO313488B1 (no) 2002-10-14
HUP9900799A2 (hu) 1999-09-28

Similar Documents

Publication Publication Date Title
SK282607B6 (sk) Farmaceutický prostriedok obsahujúci uhličitan lantanitý, spôsob prípravy tejto zlúčeniny a jej použitie
CA1334574C (en) Azithromycin and derivatives as antiprotozoal agents
US6048851A (en) Solid pharmaceutical compositions for the oral administration of gallium
US5258376A (en) Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones
US2791609A (en) Tetracycline metallo-phosphate complexes and method preparation
CA1094289A (en) Aluminum compound and medicament containing it
JP3348849B2 (ja) ３−ヒドロキシ−４−ピロンのガリウム錯体の医薬組成物
CZ20011998A3 (cs) Troferutin s vysokým obsahem trihydroxietylrutinu a způsob jeho výroby
CN1146565C (zh) 结晶性氮杂双环[2,2,2]辛烷-3-胺衍生物的柠檬酸盐的多晶型物及其药物组合物
EP0299910A2 (de) Metallhaltige Oligosaccharid-Polysulfate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel
US3839317A (en) Digoxin complexes
RU2021260C1 (ru) Соли акриловой кислоты, проявляющие цитопротекторную и противоязвенную активность, и состав, обладающий цитопротекторной и противоязвенной активностью
RU2072993C1 (ru) Способ получения соли 1, 4, 10, 13-тетраокса-7,16-диазациклооктадекан-n,n'-дималоновой кислоты
US4215143A (en) Anti-ulcer pharmaceutical composition containing inositol hexasulfate aluminum or sodium aluminum salt as active ingredient
KR810000112B1 (ko) 신규의 알루미늄 화합물의 제조방법
JPH0455737B2 (ja)
CZ20003716A3 (cs) Forma VI 5,6-dichlor-2-(isopropylamino)-l-betaL-ribofuranosyl-lH-benzimidazolu

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20160319

SPCE Expiry of an spc

Spc suppl protection certif: 65, PDO 6-2006

Effective date: 20190319